Alkermes to Host Conference Call to Discuss Financial Results for Second Quarter of Fiscal 2010
Alkermes, Inc. (NASDAQ: ALKS) will host a conference call at 4:30 p.m.
ET on Thursday, November 5, 2009, to discuss the company’s financial
results for the second quarter of fiscal 2010. Management will review
the quarter and provide an update on the company.
The conference call will be webcast on the investor relations section of
Alkermes’ website at www.alkermes.com
or may be accessed by dialing 1-888-424-8151 for domestic callers and
1-847-585-4422 for international callers. The conference call ID number
is 6332284.
A replay of the conference call will be available from 7:30 p.m. ET on
Thursday, November 5, 2009, through 5:00 p.m. ET on Thursday, November
12, 2009, and may be accessed by visiting Alkermes’ website or by
dialing 1-888-843-8996 for domestic callers and 1-630-652-3044 for
international callers. The replay access code is 6332284.
About Alkermes
Alkermes, Inc. is a fully integrated biotechnology company committed to
developing innovative medicines to improve patients' lives. Alkermes
developed, manufactures and commercializes VIVITROL® for
alcohol dependence and manufactures RISPERDAL® CONSTA®
for schizophrenia and bipolar I disorder. Alkermes' robust pipeline
includes extended-release injectable, pulmonary and oral products for
the treatment of prevalent, chronic diseases, such as central nervous
system disorders, addiction and diabetes. Headquartered in Cambridge,
Massachusetts, Alkermes has research facilities in Massachusetts and a
commercial manufacturing facility in Ohio.
(c) 2009 Business Wire, Inc., All rights reserved. All of the news releases and other content contained herein are protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Business Wire's members, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. Any copying or reproduction (other than for an individual user's personal reference), redistribution, reposting or other transmission or communication is expressly prohibited without prior written permission of Business Wire, Inc
